Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment

Acta Psychiatrica Scandinavica

Volumn 122, Issue 6, 2010, Pages 461-469

  Hunter, A M ^a,b   Leuchter, A F ^a,b   Cook, I A ^a,b   Abrams, M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressives; Depression; Neuroimaging; Side effects; Suicide

Indexed keywords

FLUOXETINE; PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; BRAIN FUNCTION; BRAIN REGION; DISEASE SEVERITY; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; NEUROPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ELECTROENCEPHALOGRAPHY; SUICIDAL IDEATION;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; CALIFORNIA; CAUSALITY; COMORBIDITY; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; FLUOXETINE; HUMANS; MALE; MOOD DISORDERS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SUICIDE;

EID: 78149369943     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01560.x     Document Type: Article

References (56)

1. Lapierre YD. Suicidality with selective serotonin reuptake inhibitors: valid claim. J Psychiatry Neurosci 2003;28:340-347.
2. Yerevanian BI, Koek RJ, Feusner JD, Hwang S, Mintz J. Antidepressants and suicidal behavior in unipolar depression. Acta Psychiatr Scand 2004;110:452-458.
3. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163:41-47.
4. Beasley CM, Ball SG, Nilsson ME. Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials. J Clin Pharmacol 2007;27:682-686.
5. Isacsson G, Holmgren A, Osby U et al. Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995-2005. Acta Psychiatr Scand 2009;120:37-44.
6. Tondo L, Lepri B, Baldessarini RJ. Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder. Acta Psychiatr Scand 2008;118:106-115.
7. Castelpietra G, Morsanutto A, Pasclo-Fabrici E et al. Antidepressant use and suicide prevention: a prescription database study in the region Friuli Venezia Giulia, Italy. Acta Psychiatr Scand 2008;118:382-388.
8. Perlis RH, Purcell S, Fava M et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007;64:689-697.
9. Perlis RH, Beasley CM, Wines JD. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 2007;76:40-46.
10. Teicher MH, Glod CA, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-210.
11. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993;8:186-212.
12. King RA, Riddle MA, Chappel PB et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991;30:179-186.
13. Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci 2003;28:331-337.
14. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004;292:807-820.
15. U.S. Food and Drug Administration. Public health advisory on cautions for use of antidepressants in adults and children, 2004. Available at:
16. Simon GE. How can we know whether antidepressants increase suicide risk?. Am J Psychiatry 2006;163:1861-1863.
17. Laje G, Paddock S, Manji H et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007;164:1530-1538.
18. Sackeim HA, Prohovnik I. Brain imaging studies of depressive disorders. In: Mann JJ, Kupfer DJ, eds. The biology of depressive disorders, Part A: a systems perspective. New York: Plenum, 1993:205-258.
19. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 2002;12:527-544.
20. Hunter AM, Cook IA, Leuchter AF. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. Psychiatr Clin North Am 2007;30:105-124.
21. Cook IA, O'hara R, Uijtdehaage SHJ, Mandelkern M, Leuchter AF. Assessing the accuracy of topographic EEG mapping for determining local brain function. Electroencephalogr Clin Neurophysiol 1998;107:408-414.
22. Leuchter AF, Uijtdehaage SH, Cook IA, O'hara R, Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res 1999;90:125-140.
23. Leuchter AF, Cook IA, Uijtdehaage SH, Lufkin RB, Andertson-Hanley C, Abrams M. Brain structure and function, and the outcomes of treatment for depression. J Clin Psychiatry 1997;58:22-31.
24. Cook IA, Leuchter AF. Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry 2001;6:113-120.
25. Cook IA, Leuchter AF, Morgan M, Witte E, Stubbeman WF, Abrams M. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 2002;27:120-131.
26. Cook IA, Leuchter AF, Morgan M, Stubbeman W, Seigman B, Abrams M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J Psychiatry Res 2005;39:461-466.
27. Bares M, Brunovsky M, Kopecek M et al. Changes in QEEG prefrontal activity as a predictor of response to antidepressive medication in patients with treatment resistant depressive disorder: a pilot study. J Psychopharmacol 2007;41:319-325.
28. Bares M, Brunovsky M, Kopecek M et al. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur Psychiatry 2008;23:350-355.
29. Kopecek M, Bares M, Brunovsky M, Stokova P, Novak T, Kozeny J. EEG cordance as a predictor of response to antidepressive medication - pooled analysis; 14th European Congress of Psychiatry. Nice, France: Association of European Psychiatrists (AEP), 2006.
30. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002;159:122-129.
31. Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (QEEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry 2006;163:1426-1432.
32. Leuchter AF, Cook IA, Debrota DJ, Hunter AM, Potter WZ, Mcgrouther CC. Changes in brain function (QEEG cordance) during administration of venlafaxine or placebo to normal subjects. Clin EEG Neurosci 2008;39:175-181.
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
34. First MB, Spitzer RL, Gibbon M, Williams JBW Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute, 1996.
35. Derogatis LR Symptom checklist-90-R: administration, scoring and procedures manual, 3rd edn. Minneapolis: National Computer Systems, 1994.
36. Cook IA, Leuchter AF, Uijtedehaage SHJ et al. Neurophysiologic predictors of treatment response to fluoxetine in major depression. Psychiatry Res 1999;85:263-273.
37. Marascuilo LA, Levin JR. Appropriate post hoc comparisons for interaction and nested hypotheses in analysis of variance designs: the elimination of type IV errors. Am Educ Res J 1970;7:397-421.
38. Cook IA, Hunter AM, Abrams M, Seigman B, Leuchter AF Midline and right frontal brain function and remission in Major Depression. Psychiatry Res Neuroimaging 2009;174:152-157.
39. Asberg M, Traskman L, Thoren P. 5-HIAA in cerebrospinal-fluid-biochemical suicide predictor. Arch Gen Psychiatr 1976;33:1193-1197.
40. Audenaert K, Van Laere K, Dumont F, Slegers G, Mertens J, Van Heeringen C. Decreased frontal serotonin 5-HT2A receptor binding index in deliberate self-harm patients. Eur J Nucl Med 2001;28:175-182.
41. Leyton M, Paquette V, Gravel P et al. Alpha-[(11)C]Methyl-l-tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide attempters. Eur Neuropsychopharmacol 2006;16:220-223.
42. Audenaert K, Goethals I, Van Laere K et al. SPECT neuropsychological activation procedure with the verbal fluency test in attempted suicide patients. Nucl Med Commun 2002;9:907-916.
43. Oquendo MA, Placidi GPA, Malone KM, Campbell C, Keilp J, Brodsky B. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. Arch Gen Psychiatr 2003;60:14-22.
44. Audenaert K, Peremans K, Goethals I et al. Functional imaging of the suicidal brain. Nucl Med Commun 2005;26:391-393.
45. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimized treatment. Br Med Bull 2003;65:193-207.
46. Asada H, Fukudea Y, Tsunoda S, Yamaguchi M, Tonoike M. Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neurosci Lett 1999;274:29-32.
47. Ishii R, Shinosaki K, Ukai S, Inouye T, Ishihara T, Yoshimine T. Medial prefrontal cortex generates frontal midline theta rhythm. Neuroreport 1999;10:675-679.
48. Pizzagalli DA, Oakes TR, Davidson RJ. Coupling of theta activity and glucose metabolism in the human rostral anterior cingulate cortex: an EEG/PET study of normal and depressed subjects. Psychophysiology 2003;40:939-949.
49. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997;8:i-ii.
50. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, Oakes TR, Larson CL, Abercrombie HC. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry 2001;158:405-415.
51. Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003;160:64-75.
52. Vlassenko A, Sheline YI, Fischer K, Mintun MA. Cerebral perfusion response to successful treatment of depression with different serotoninergic agents. J Neuropsychiatry Clin Neurosci 2004;16:360-363.
53. Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL. Suicidality as a possible side effect of antidepressant treatment. J Clin Psychiatry 2004;65:742-749.
54. Iosifescu DV, Greenwald S, Devlin P et al. Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder. Acta Psychiatr Scand 2008;117:271-276.
55. Beck AT, Brown GK, Steer RA. Psychometric characteristics of the Scale for Suicide Ideation with psychiatric outpatients. Behav Res Ther 1997;35:1039-1046.
56. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007;164:1035-1043.